血癌,淋巴瘤 z-bo 2020-09-17 355

　　Lymphoma of the marginal zone of the spleen is a rare cancer. It usually develops very slowly, and patients start treatment only when the doctor thinks that treatment is needed. The disease accounts for 3% of all lymphoma patients. There is very little research on the pathogenesis of the disease. Professor Jonathan Strefford said that by revealing the genetic manifestations related to the poor prognosis of the disease, doctors can determine which patients will develop malignant cancers and which patients need high-dose drugs or therapies in the early stages of the disease.

　　In the article, the researchers revealed for the first time that genetic defects associated with splenic marginal zone lymphoma can affect the prognosis of patients; errors in the TP53 gene in cancer cells are considered to be the cause of cancer, and the existence of KLF2 and NOTCH2 gene defects At the same time, it also reveals that patients need rapid and concentrated treatment.

　　Understanding the different genetic changes that cause the patient's disease will help researchers design new therapies to help treat a variety of different blood cancers, but so far, researchers have been helpless with regard to lymphoma in the marginal zone of the spleen. This study may help doctors and Patients learn more about the onset of the disease and help researchers develop potential therapies to effectively improve the symptoms of patients with lymphoma in the marginal zone of the spleen.